Menu
Recruiting NCT07481630

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Phase III Interventional Obesity Knee Osteoarthritis (OA)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: NNC0487-0111, Placebo (matched to NNC0487-0111 ).
Who it may be relevant to
Registry conditions: Obesity, Knee Osteoarthritis (OA). Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States, Australia, Bulgaria, Canada, Denmark +5
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Knee Osteoarthritis (AMAZE 5)

Overview

The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and knee osteoarthritis. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.

Interventions

  • Drug NNC0487-0111
    NNC0487-0111 dose level 1 and dose level 2 will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.
  • Drug Placebo (matched to NNC0487-0111 )
    Placebo matched to NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

Primary outcome measures

  • Relative change in body weight [Time frame: From baseline (week 0) to (week 80)]
  • Change in WOMAC Osteoarthritis Index NRS 3.1 (24-hour) (WOMAC) pain score [Time frame: From baseline (week 0) to (week 80)]
Secondary outcome measures (12)
  • Change in WOMAC physical function score [Time frame: From baseline (week 0) to (week 80)]
  • Change in SF-36v2® Health Survey Acute (SF-36v2 Acute) physical functioning score [Time frame: From baseline (week 0) to (week 80)]
  • Change in body weight [Time frame: From baseline (week 0) to (week 80)]
  • Change in body mass index (BMI) [Time frame: From baseline (week 0) to (week 80)]
  • Change in WOMAC stiffness score [Time frame: From baseline (week 0) to (week 80)]
  • Change in WOMAC total score [Time frame: From baseline (week 0) to (week 80)]
  • Change in waist circumference [Time frame: From baseline (week 0) to (week 80)]
  • Change in systolic blood pressure (SBP) [Time frame: From baseline (week 0) to (week 80)]
  • Change in diastolic blood pressure (DBP) [Time frame: From baseline (week 0) to (week 80)]
  • Change in total cholesterol [Time frame: From baseline (week 0) to (week 80)]
  • Change in high-density lipoprotein (HDL) cholesterol [Time frame: From baseline (week 0) to (week 80)]
  • Change in low-density lipoprotein (LDL) cholesterol [Time frame: From baseline (week 0) to (week 80)]

Eligibility criteria

Inclusion criteria

  • Male or female (sex at birth).
  • Age 18 years or above at the time of signing the informed consent.
  • Clinical diagnosis of knee osteoarthritis (American College of Rheumatology criteria) with radiographic changes (Kellgren Lawrence (KL) grades 2 to 3 as per central reading) in target knee. Target knee joint is defined as most symptomatic knee at screening. If pain in knees is equal, the target knee joint will be the dominant leg.
  • Symptomatic knee OA with first appearance of pain in the target knee more than (>) 90 days prior to screening and pain in the target knee for > 15 days over the prior 30 days.
  • Willingness to complete a 72-hour washout period of analgesics before all visits involving WOMAC Osteoarthritis Index NRS 3.1 (24-hour) (WOMAC) questionnaire (acetaminophen 4 gram (g)/day is allowed as rescue medication up until 24 hours before those visits).

Exclusion criteria

  • Glycated haemoglobin more than or equal to (≥) 6.5% \[(48 millimoles per mole (mmol/mol)\] as measured by the central laboratory at screening.
  • History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records.
  • Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment), or amylin analogues before screening.
  • Any joint prosthesis or joint replacement in target knee.
  • Arthroscopy or injections into target knee within the last 90 days prior to screening.
  • Any other joint disease in target knee including gout and pseudogout.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Treatment

Study locations

United States · 19 centers
  • Arizona Research Center, Inc. — Phoenix
  • Diablo Clinical Research, Inc. — Walnut Creek
  • Chase Medical Research LLC — Hamden
  • Chase Medical Research LLC — Waterbury
  • Zenith clinical research — Hollywood
  • CNS Healthcare — Jacksonville
  • Angels Clinical Research Institute — Miami Lakes
  • Hope Clin Res & Wellness — Conyers
  • … and 11 more centers
Poland · 12 centers
  • "Zdrowie Osteo-Medic" s.c. Lidia i Artur Racewicz, Agnieszka i Jerzy Supronik — Bialystok
  • "Zdrowie Osteo-Medic" s.c. Lidia i Artur Racewicz, Agnieszka i Jerzy Supronik — Bialystok
  • ClinicMed Daniluk, Nowak Spółka Komandytowa — Bialystok
  • ClinicMed Daniluk, Nowak Spółka Komandytowa — Bialystok
  • Centrum Medyczne Intercor Sp. z o.o. — Bydgoszcz
  • Centrum Medyczne Intercor Sp. z o.o. — Bydgoszcz
  • CenterMed Kraków Sp. z o.o. — Krakow
  • CenterMed Kraków Sp. z o.o. — Krakow
  • … and 4 more centers
Spain · 11 centers
  • Instituto Medico Quirurgico San Rafael — A Coruña
  • Hospital Germans Trias i Pujol — Badalona
  • Hospital Naval Ferrol — Ferrol
  • Centro Especialidades Hermanos Sangro — Madrid
  • Hospital Quirónsalud Málaga — Málaga
  • Hospital Infanta Sofía — San Sebastián de Los Reyes (Madrid)
  • Hospital Universitario Marqués de Valdecilla — Santander
  • Hospital HM La Esperanza — Santiago de Compostela
  • … and 3 more centers
Greece · 7 centers
  • University General Hospital Attikon General Hospital Of West Attica H Agia Varvara - 2nd d — Chaïdári
  • Laiko General Hospital Of Athens - 1st department of Internal Medicine — Athens
  • Athens Medical Center S.A. (Iatriko Psychikou) - Department of Internal Medicine & Metabol — Athens
  • General Hospital Of Athens Alexandra - Clinical Therapeutics — Athens
  • Athens Medical Center S.A. (Iatriko Athinon) - Diabetes and Obesity Unit — Marousi
  • NextHealth S.A. - Department of Endocrinology, Metabolism & Diabetes — Thessaloniki
  • Thermi Clinic S.A. - Diabetes and Internal Medicine Department — Thessaloniki
Italy · 7 centers
  • AOU Federico II Di Napoli - DAI Endocr. Diab. Andro. e Nutr. - UOC Medicina Interna e Nutr — Naples
  • Ospedale Civile di Baggiovara - UOC Endocrinologia — Modena
  • Ospedale S. Maria della Misericordia - Reparto Endocrinologia e Malattie del Metabolismo — Udine
  • Pol. Uni. Campus Biomedico - UOC Endocrinologia e Diabetologia — Rome
  • Auxologico San Luca - Endocrinologia e Malattie del Metabolismo — Milan
  • Policlinico San Donato di Milano S.p.A - UOS Endocrinologia e del Servizio di Nutrizione C — San Donato Milanese
  • Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Civile Maggiore Borgo Trento — Verona
Turkey (Türkiye) · 7 centers
  • Ankara Üniversitesi Sağlık Uygulama ve Araştırma Hastaneleri- Fiziksel Tıp ve Rehabilitasy — Altındağ/Ankara
  • İstanbul Fizik Tedavi ve Rehabilitasyon Eğitim ve Araştırma Hastanesi — Bahçelievler/İstanbul
  • Ankara Bilkent Şehir Hastanesi- Fizik Tedavi ve Rehabilitasyon — Çankaya/Ankara
  • Çanakkale Onsekiz Mart Üniversitesi Sağlık Araştırma ve Uygulama Hastanesi-Fiziksel Tıp ve — Kepez/Çanakkale Merkez/Çanakkale
  • İnönü Üniversitesi Turgut Özal Tıp Merkezi Hastanesi-Fiziksel Tıp ve Rehabilitasyon — Merkez/Battalgazi/Malatya
  • … and 2 more centers
Bulgaria · 6 centers
  • UMHAT Sveti Georgi EAD, Plovdiv — Plovdiv
  • MC Dr. Atanasov EOOD — Sofia
  • MC Excelsior OOD — Sofia
  • UMHAT Tsaritsa Yoanna - ISUL EAD, Orthopaedics and Traumatology — Sofia
  • MMA MHAT - Sofia, Rheumatology clinic — Sofia
  • UMHAT Sveti Ivan Rilski EAD, Rheumatology — Sofia
Australia · 5 centers
  • Emeritus Research Sydney — Botany
  • Momentum Clinical Research Darlinghurst — Darlinghurst
  • Kolling Institute — St Leonards
  • Heart of Australia — Chelmer
  • Coastal Digestive Health — Maroochydore
Canada · 5 centers
  • Laser Rejuvenation Clinics Inc. — Calgary
  • Dawson Clinical Research — Guelph
  • Hamilton Medical Rsrch Grp — Hamilton
  • Centre de Recherche Musculo — Trois-Rivières
  • Alpha Recherche Clinique - Lebourgneuf — Québec
Denmark · 3 centers
  • Aarhus Universitetshospital - Klinik for Led og bindevævssygdomme — Aarhus N
  • Frederiksberg Hospital - Parker Institutet (Artrose) — Frederiksberg
  • Sanos Clinic - Herlev — Herlev

Identifiers

NCT: NCT07481630 · NN9490-8026 · U1111-1313-6585 · 2024-520444-42

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗